Faron´s Annual Report 2023
In brief · summary, not quotable
No summary for this filing – the full text is below.
Full announcement
Select text to share a quote on X · sign in to keep highlights & notes in your FARN notes
| TURKU, Finland / BOSTON, Massachusetts - March 26, 2024 - Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company pursuing a CLEVER approach to reprogramming myeloid cells to activate anti-tumor immunity in hematological and solid tumor microenvironments, announces today that its Annual Report for the year 2023 and audited financial statements for the accounting period January 1- December 31, 2023 in English, and its financial statements in Finnish are now available on the Company's website: Faron Full-year results for the twelve months ended December 31, 2023 | Faron |
About Bexmarilimab
About Faron Pharmaceuticals Ltd.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.